EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2

The invention relates to preparing and using recombinant expression vectors for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2. One expression vector contains the recombinant human adenovirus serotype26 genome, wherein the E1 and E3 regions are deleted, and the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NARODITSKY, Boris Savelievich, TOKARSKAYA, Elizaveta Alexandrovna, ZUBKOVA, Olga Vadimovna, ESMAGAMBETOV, Ilias Bulatovich, POPOVA, Olga, BORISEVICH, Sergey Vladimirovich, TUKHVATULIN, Amir Ildarovich, GROUSOVA, Daria Mikhailovna, TUKHVATULINA, Natalia Mikhailovna, BOTIKOV, Andrei Gennadevich, DZHARULLAEVA, Alina Shahmirovna, SHCHERBININ, Dmitrii Nikolaevich, GINTSBURG, Aleksandr Leonidovich, OZHAROVSKAIA, Tatiana Andreevna, NIKITENKO, Natalya Anatolevna, LOGUNOV, Denis Yuryevich, DOLZHIKOVA, Inna Vadimovna, SHCHEBLIAKOV, Dmitrii Viktorovich, EROXOVA, Alina Sergeevna, SEMIKHIN, Aleksandr Sergeevich
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to preparing and using recombinant expression vectors for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2. One expression vector contains the recombinant human adenovirus serotype26 genome, wherein the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 1). Therein, SEQ ID NO:5 was a parental sequence of human adenovirus serotype 26.Another expression vector contains the recombinant simian adenovirus serotype25 genome, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:4, 2, or 3 (variant 2). Therein, SEQ ID NO:6 was a parental sequence of simian adenovirus serotype 25.Further, the recombinant human adenovirus serotype5 genome is disclosed, wherein the E1 and E3 regions are deleted, with an integrated expression cassette of SEQ ID NO:1, 2, or 3 (variant 3). Therein, SEQ ID NO:7 was a parental sequence of human adenovirus serotype 5.